Purpose

The goal of this study is to evaluate imaging biomarkers for quantitative assessments of myofascial pain and determine their ability to monitor treatment response and predict clinical outcomes.

Condition

Eligibility

Eligible Ages
Between 18 Years and 80 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  1. Adults between the ages of 18 and 80 years old. 2. History of spontaneous (non-provoked) pain in the neck and/or shoulder region lasting at least 3 months. Neck and/or shoulder pain, unilateral or bilateral. 3. Presence of a palpable myofascial trigger point (MTrP) in one or both upper trapezius muscles. 4. The participant has a Numeric Pain Rating Scale of 4/10 or more in the last one week, and the pain is reproducible by palpating the trigger point. 5. Pain localized to the area of the trigger point that is reproduced or worsened upon palpation. 6. Radiation of pain to the head, neck, or face with palpation is allowed but not required.

Exclusion Criteria

  1. Age <18 or >80 years old. 2. Acute cervical spine pathology, trauma (e.g. whiplash) or cervical radiculopathy 3. History of surgery involving the head, neck, or shoulder girdle. 4. Presence of neuromuscular pathologies or inflammatory muscle diseases (e.g. dermatomyositis) 5. Systemic disease with diffuse body pain (e.g. system lupus erythematosus) 6. Peripheral neuropathy 7. Cancer-related pain 8. Pregnancy, coagulopathy or other bleeding disorder, fever, general/local infection at the pain site, substance abuse, or any other diseases that may account for signs and symptoms mimicking myofascial pain. 9. Contraindication to MRI 10. Chronic fatigue syndrome, fibromyalgia, or chronic Lyme disease. 11. Use of acupuncture or changes in pain medications within 6 weeks of enrollment. 12. Receipt of Botox injection to the neck/shoulder region within the past 3 months or trigger point injection within the past 6 weeks.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Triple (Participant, Investigator, Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Active Comparator
Chemical Injection
Local chemical injection at clinician-identified myofascial trigger points.
  • Drug: 50/50 Mixture of Lidocaine 1% injection + Bupivacaine 0.25% Injectable Solution
    Treatment Group: Receives trigger-point injection with a 50/50 mixture of 1% lidocaine and 0.25% bupivacaine
Placebo Comparator
Dry Needle
Dry needling at clinician-identified myofascial trigger points.
  • Procedure: Dry Needling
    Single session of dry needling to the identified trigger point(s) per protocol.

Recruiting Locations

Washington University in St. Louis and nearby locations

Washington University
St Louis, Missouri 63110
Contact:
Andre Guthrie, BS
3142732556
guthriea@wustl.edu

More Details

NCT ID
NCT07322445
Status
Recruiting
Sponsor
Washington University School of Medicine

Study Contact

Andre Guthrie, BS
3142732556
guthriea@wustl.edu

Detailed Description

This Phase 2 randomized clinical trial builds upon findings from Phase 1, which identified candidate imaging biomarkers of myofascial pain. The study will assess whether these biomarkers can monitor responses to local chemical injection treatment and predict clinical outcomes. Participants with neck/shoulder pain and the presence of active myofascial trigger points will be referred from pain management clinics or recruited through the Volunteer for Health office. Eligible participants will undergo multi-modal imaging procedures, including magnetic resonance imaging (MRI), surface electromyography (sEMG), and fiber-optic imaging. Participants will then be randomized to receive either chemical injection or dry needling at the identified trigger points. Over the course of two study visits, spaced approximately two weeks apart, participants will complete imaging procedures and patient-reported outcome questionnaires. The study team will analyze imaging and clinical data to evaluate the capacity of identified biomarkers to detect treatment-related changes and to predict longer-term clinical response.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.